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Targeted biological therapies for hepatocellular cancer have shown minimal improvements in median survival. Multiple pathways
to oncogenesis leading to rapid development of resistance to such therapies is a concern. Non-invasive radiofrequency ﬁeld-
induced targeted hyperthermia using nanoparticles is a radical departure from conventional modalities. In this paper we
underscore the need for innovative strategies for the treatment of hepatocellular cancer, describe the central paradigm of targeted
hyperthermia usingnon-invasiveelectromagnetic energy, review theprocess ofcharacterizationandmodiﬁcationofnanoparticles
for the task, and summarize data from cell-based and animal-based models of hepatocellular cancer treated with non-invasive RF
energy. Finally, future strategies and challenges in bringing this modality from bench to clinic are discussed.
1.Introduction
Hepatocellularcancer(HCC)presentsaglobalchallenge.Itis
the sixth most common cancer and the third most common
cause of cancer-related deaths worldwide [1]. The incidence
of HCC is on the rise. It is estimated that approximately
1 million new cases of HCC are diagnosed each year [2].
Chronic infection with hepatitis B and hepatitis C virus cou-
pled with other risk factors such as diabetes, obesity, smok-
ing, and heavy alcohol consumption contribute to this rising
incidence [3]. Growing burden of disease presents a signif-
icant problem, as majority of patients diagnosed with HCC
cannot be treated with curative intent [4]. This is because
of delay in diagnosis and concomitant hepatic dysfunction.
Worldwide, the median survival of patients with advanced
HCC who remain untreated is less than 4 months [5].
Surgical resection and transplantation yield 5-year sur-
vivals ranging from 35% to over 70% [4, 6–10]. These
therapies are suited for few candidates that have limited
local disease and ﬁt into a strict clinical criteria. For other
patients with HCC, treatment options include intratumoral
injection of absolute ethanol or acetic acid, invasive thermal
destruction using microwave or radiofrequency needles and
transarterial chemoembolization (TACE) using drug-eluting
beads. Considered together, local-regional therapies have
lead to a modest increase in median survival [11].
While targeted biological therapies such as monoclonal
antibodies have been successful in treating other cancers,
HCC remains a challenge. Recently Sorafenib, a multikinase
inhibitor, has shown an improvement in median survival
of 2.3–2.8 months compared to placebo in clinical trials
[12,13].Futilityofbiologicaltherapiesisbecause ofmultiple
pathways to oncogenesis in HCC and rapid development
of resistance to these agents. Non-invasive electromagnetic
ﬁeld-induced targeted hyperthermia for the treatment of
HCC is a radical departure from traditional therapies and
holds immense potential.
Electromagnetic energy in the form of near-infrared
(NIR) photothermal energy, inductively coupled magnetic
ﬁeld or radiofrequency ﬁeld, has been employed to deliver
non-invasive targeted hyperthermia to malignant cells [14–
17]. The rationale for such therapies is based on the
observation that metal nanoparticles targeted to tumor
cells generate heat when exposed to electromagnetic energy2 International Journal of Hepatology
causing them to undergo heat-stress-triggered apoptosis
while sparing normal tissues. The use of non-invasive NIR
energy to produce photothermal toxicity is limited by its low
tissue penetrance and hence inability to treat deeper lesions
as in HCC[18].Useofinductivelycoupledmagnetic ﬁeldsto
heat charged magnetic dextran-coated metal nanoparticles
such as iron oxide (Fe3O4) has also been demonstrated.
However, thermal enhancement is limited by the magnetic
ﬁeld strength applicable to abdominal tumors (<4.5kA/m,
100kHz) and by diﬃculty in targeting magnetic nanopar-
ticles to malignant cells [16, 17]. In contrast, non-invasive
radiofrequency ﬁeld-induced heating of metal nanoparticles
oﬀers several advantages over others in the treatment of
HCC, as detailed later. The purpose of this paper is to
summarize current strategies for delivering non-invasive
radiofrequency ﬁeld-mediated hyperthermia to malignant
cells and its application to HCC.
2.RadioWavesintheTreatmentofCancer
Radio waves are low-frequency electromagnetic waves that
havelowtissue-speciﬁc absorptionrate(SAR)and,therefore,
excellent whole body tissue penetration. Radio waves are
considered safe with several studies reporting no harmful
eﬀects in humans exposed to RF ﬁeld for several hours [19,
20]. Becauseoftheirexcellent safety proﬁle,radio waveshave
been widely utilized in medicine including communication
devices, diagnostic imaging, and ablation therapies.
Radiofrequency ablation (RFA) has particularly been
eﬀective for local regional control of HCC in patients not
amenable to surgical resection or awaiting transplantation.
This technique requires high RF energy transfer from an
electrode placed within the tumor percutaneously or intrao-
peratively under image guidance. Energy dissipated through
the RF electrode causes coagulative necrosis and thermal
destruction of the tumor [21]. In contrast to RFA, nano-
particle targeted hyperthermia is a non-invasive approach
to deliver hyperthermia at a cellular level without harming
surrounding normal tissue (Figure 1).
3.KanziusRF Generator
Non-invasive radiofrequency-based hyperthermia, unlike
radiofrequency ablation, requires an external radiofrequency
ﬁeld generator (Kanzius RF generator) [14, 22, 23]. This is
a variable power (0–2KW) 13.56MHz RF ﬁeld generator
(Therm Med LLC, Erie, Pennsylvania). The RF generator
is connected to a high Q coupling system with a Tx head
(focused end-ﬁred antenna circuit) and reciprocal Rx head
(as a return for the generator) mounted on a swivel bracket
allowing the RF ﬁeld to be oriented in either a horizontal or
vertical direction (Figure 2). The distance between the two
heads is adjustable. The coaxial end-ﬁre circuit in the Tx
head produces an electronic focused RF ﬁeld up to 15cm
in diameter. The electromagnetic ﬁeld strength between the
Tx and Rx head is established and calibrated in a Faraday-
shielded room to exclude any interference from external
RF sources. The ﬁeld is measured using a Hewlett Packard
SpectrumAnalyzer(model 8566B,Agilent,Santa Clara, CA),
an isotropic ﬁeld monitor, and a probe (models FM2004 and
FP2000, Ampliﬁer Research Inc., Souderton, PA). Utilizing
an output power of 600W, maximum electric ﬁeld strength
(Ep) of 12.4kV/m is measured at a distance 2.5cm from the
Tx head.
4.Radiofrequency-Induced
HeatingofNanoparticles
We have demonstrated heating of several nanoparticles in
the RF ﬁeld including gold nanoparticles (AuNP), gold
silica nanoshells, single-walled carbon nanotubes (SWNT),
and water-soluble derivatives of C60 fullerenes [14, 22–
27]. A treatment strategy based on molecular targeting of
gold and carbon nanoparticles has several advantages: they
are simple and inexpensive to synthesize; they are easily
characterized duetotheirsignatureopticalabsorptions; their
surface chemistry readily permits manipulation of charge
and shape and attaching cancer cell-targeting molecules,
including antibodies, peptides, or pharmacologic agents, is
easilyachieved.Adetaileddiscussiononthemethodsutilized
to characterize and synthesize such nanoparticles is beyond
the scope of this paper and is described elsewhere.
Heating of AuNPs in RF ﬁeld is concentration and size
dependentasshown inFigure 3.A uNP swithsmalldiamet ers
(5nm) heat better than larger particles. In our previous
papers we have explained the increased heating of smaller
particles on the basis of increased ohmic dissipation with
increased resistivity of smaller particles [28]. The exact
physical basis of heat generation by nanoparticles is not
entirely clear and is an area of active investigation.
Similar to AuNPs, single-walled carbon nanotubes
(SWNT)functionalizedwithabiocompatiblenonionicpoly-
mer (Kentera) demonstrate a linear rise in temperature after
RF activation [26]. The heating rate also increases linearly
with RF generator output power. However, the heating rate
of SWNT suspensions increases nonlinearly with increasing
concentrations (Figure 4).
5.TargetingStrategies
In order to deliver targeted hyperthermia to cancer cells it
is crucial that the nanoparticles are modiﬁed to speciﬁcally
enhanceuptakebytumorcells.Inourstudies,wehaveconju-
gated monoclonal antibodies (raised against tumor-speciﬁc
targets) to nanoparticles. Two approaches are described
here using chimeric anti-epidermal growth factor receptor
(EGFR) antibody (or C225) conjugation to AuNPs as a
prototypical example.
Noncovalent Conjugation. Colloidal suspensions of spherical
AuNPs are stabilized during synthesis using citrate as a
stabilizing agent to prevent aggregation. For the purposes of
conjugation the AuNPs are concentrated to remove citrate.
These are then resuspended in a buﬀer solution whose pH
matches the isoelectric point of the monoclonal antibody
(pH= 8.5forC225).The monoclonalantibody isthenslowly
added to AuNP colloidal suspension in a (w/w) ratio of
20:50 and gently mixed. Surface modiﬁcation is conﬁrmedInternational Journal of Hepatology 3
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Figure 1: Principle of the non-invasive RF based treatment of HCC. A. RF ﬁeld source is used to generate a uniform low frequency
electromagnetic ﬁeld that penetrates tissues and reaches the tumor. B. Nanoparticles that can be thermally activated are conjugated to
monoclonal antibodies against known targets expressed on HCC (i), internalized speciﬁcally by cancer cells after systemic administration
(ii), and upon RF activation release heat (iii) causing targeted cancer cell death.
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Ground plate
Figure 2: Kanzius RF generator: RF ﬁeld source transmission
antenna (Tx head) and ground plate (Reciprocal Rx head) are
separated by 10cm air-gap. Samples are placed 2.5cm from the Tx
head on the Teﬂon holder.
by <10nm red shift in UV-Vis peak absorption spectra
of modiﬁed AuNPs. While easy to perform, NonCovalent
conjugation is nondirectional. Moreover, other proteins in
biological samples can replace surface-bound antibodies.
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Figure 3: Size-dependent heating of gold nanoparticles in non-
invasive RF ﬁeld. 150nm gold nanoshells (a shell thickness of 10–
15nm) demonstrate heating rates similar to 5nm gold nanoparti-
cles. Reproduced with permission from Nano Research, vol. 2, no. 5,
pp. 400-405, 2009.
Thiol-Based Covalent Linkage. Near covalent bonds can be
formed on the surface of AuNP when monoclonal anti-
bodies are attached to linker with a thiol functional group.
Thiol-based conjugation is stronger and more stable than
NonCovalent electrostatic interaction and hence preferred.
Directional conjugation also presents Fab portion of the4 International Journal of Hepatology
antibody to the tumor antigens maximizing receptor-ligand
interaction. We have employed methods described by Kumar
et al. with slight modiﬁcations [29].
6.In Vitro ThermalCytotoxicityof
RF-InducedHyperthermia
We have demonstrated the eﬀect of RF treatment on various
heptaocellular cancer cell lines using diﬀerent nanoparticles.
Hep3B and HepG2 cells treated with kentera modiﬁed
SWNT were exposed to an 800W RF ﬁeld [26]. Signiﬁcant
thermal cytotoxicity was demonstrated with 2 minutes of RF
exposureinaconcentration-dependentmanner. Highercon-
centrations (500mg/L) produced 100% thermal cytotoxicity
in comparison to untreated controls (11%) and cells treated
with kentera solution only (35%), P value <. 01.
In separate experiments, Hep3B cells were exposed to
naked 5nm AuNPs at 1, 10, or 67μMf o r2 4h o u r s[ 27].
The gold containingmedium was aspirated and replaced by
fresh medium. Cells were then exposed to RF treatment for
1, 2, and 5 minutes. The resulting thermal cytotoxicity is
summarized in Table 1. This RF-induced gold nanoparticle-
based thermal cytotoxicity was concentration dependent
(data not shown).
These experiments indicate that non-invasive RF ﬁeld-
based hyperthermia using untargeted nanoparticles is highly
eﬀective in treating HCC cell lines. In separate experiments,
a more targeted approach was implemented. Panc-1 cells
treated with C225-conjugated AuNP and exposed to RF
ﬁeld in RF showed higher thermal cytotoxicity than cells
treated with naked gold nanoparticles and exposed to RF
ﬁeld (data in press). Using a similar approach for HCC
presents challenges. Unlike pancreatic cancer, expression of
EGFR on HCC cell lines is moderate at best. A systematic
investigation to identify better and more speciﬁc molecular
targets on HCC is currently underway.
7.TumorResponseto RF-Induced
Hyperthermiain Animal Models
In order to demonstrate that SWNT localized to VX2 tumor
can be remotely activated by RF ﬁeld to produce thermal
cytotoxicity,adult New Zealand white rabbits bearing ortho-
topic VX2 tumors ranging in size from 1.0cm to 1.3cm
in greatest dimension underwent a direct intratumoral
injection of water-soluble SWNTs or control solutions [26].
Rabbits were treated with or without RF for 2 minutes.
Two days after RF treatment, all animals were sacriﬁced.
Histopathology sections from tumors injected with SWNTs
revealed complete thermal necrosis of the tumor tissue with
a surrounding 2mm to 5mm zone of thermal injury to
t h el i v e r .T h e r ew a sn oe v i d e n c eo fn o n s p e c i ﬁ ci n j u r yt o
otherorgans and tissues. Tumors that had been injected with
SWNTs but not treated with RF also were completely viable,
as were tumors that had not been injected with SWNTs or
control solutions and had been treated with RF alone (data
not shown).
As a next step and to develop an entirely non-invasive
treatment modality, our goal was to inject antibody-
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Figure 4: Concentration-dependent heating rate of Kentera SWNT
suspensions under 600W of RF generator output power. Sus-
pensions exhibited nonlinear heating rates with increasing SWNT
concentration. Shown are the averages of the heating rates for Ken-
tera SWNTs (dots) and the calculated SWNT heating contribution
(triangles).Reproducedwith permission fromCancer, vol.110, no. 12,
pp. 2654–2665, 2007.
Table 1: Non-invasive RF ﬁeld treatment of Hep3B cells: cell
viability was assessed by Propidium Iodide-Fluorescent Activated
Cell Sorting (PI-FACS) 18 hours after RF exposure.
RF exposure
(min)
Controls
Cell death (%)
Pretreated with
AuNP (67 μM)
Cell death (%)
P value
5 75.0 ± 12.2 99.8 ± 3.1 .4
22 1 ± 14.4 98.5 ± 0.5 .001
1 17.6 ± 8.4 99.0 ± 0.2 .001
conjugated nanoparticles systemically and allow them to
concentrate speciﬁcally in the tumor tissue. To investigate
that further and as a proof of principle, we used an ectopic
murine model of EGFR expressing Panc-1 tumors. This is
because of ease of availability and extensive characterization
of chimeric C225. C225 was directionally conjugated to
10nm AuNPs. The conjugates when systemically injected
concentrated speciﬁcally to the tumor site unlike nontar-
geted AuNPs. Weekly cycles of injection of nanoconjugates
followed by RF treatment for 10 minutes halted the growth
of tumors during 7 weeks of treatment compared to RF only,
nanoconjugates only, and untreated controls (P<. 004),
and in some cases produced a complete response (data
in press). In these in vivo experiments, no untoward or
unexplained side eﬀects were noted. We expect that as HCC-
speciﬁc tumor targets are identiﬁed, a similar approach can
be employed.
8.FutureDirectionand Challenges
In this brief paper, we have summarized the grand oppor-
tunities and challenges, non-invasive RF-based treatment ofInternational Journal of Hepatology 5
(a)
(b)
Figure 5: Photomicrographs of hepatic VX2 tumors from rabbits
that received (a) or did not receive (b) intratumoral injection of
Kentera single-walled carbon nanotubes (SWNTs) followed by 2
minutes of RF ﬁeld treatment. SWNTs (arrow) can be identiﬁed
surroundedbynecrotictumor.(RoutineH&Estain,magniﬁcation,
x400). Reproduced with permission from Cancer, vol. 110, no. 12, pp.
2654–2665, 2007
HCC presents. There areseveral advantages of using such
an approach. Radio waves have well-documented safety in
humans, mainly because of their minimal SAR. At the same
time they have excellent whole body penetration reaching
tumors in every possible location. Nanoparticles used to
harness RF electromagnetic energy within the tumor are
inexpensive and simple to synthesize with high reproducibil-
ity. They can be easily characterized using well-established
methods. They are suﬃciently small to navigate through the
most compromised tumor vasculature. In addition to this,
AuNPs are biocompatible, have not been associated with
any acute or chronic toxicity in preclinical studies, and are
already used clinically to treat severe rheumatoid arthritis.
These features make it an attractive, safe, and eﬀective
treatment modality for HCC patients including those with
hepatic dysfunction.
Identiﬁcation of HCC-speciﬁc tumor targets is an area
of active research inquiry. Attempts tocharacterize immuno-
logic diﬀerences between human HCC cells and normal
hepagtocytes led to the development of AF-20 and FB-
50 monoclonal antibodies that recognize diﬀerent domains
on overexpressed aspartyl β-hydroxylase. However, these
monoclonal antibodies are not commercially available, and
theirreceptor-ligand interaction remains tobecharacterized.
Similarly,anotherchallengeisin vivothermaldosimetry. The
need to measure real-time temperature for treatments that
employ hyperthermia has led to the development of mag-
netic resonance thermography. However it seems plausible
that the interaction of the two magnetic ﬁelds will not allow
utilization of magnetic resonance thermography for mea-
surement of RF-based hyperthermia. Other techniques that
allow real-time thermography need to be developed. Finally,
we anticipate that long-term RF-induced hyperthermia-
based treatment for HCC has the potential to induce
thermotolerance as well as thermoresistance in some subsets
of patients. Such patients may beneﬁt from enhancing eﬀects
of chemotherapeutic agents using RF-based hyperthermia,
w h i c hs h o u l da l s ob ei n v e s t i g a t e di nt h ef u t u r e .
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